Physician profile
Robert A Gianfagna
NPI 1386650943
$8,894.80
in general payments reported to CMS, 2019-2025
34 companies · $63.12 in 2025
The $63.12 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,513 · 2020: $827 · 2021: $1,140 · 2022: $1,679 · 2023: $1,627 · 2024: $1,046 · 2025: $63.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,736.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,392.90 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $938.59 | 2019-2024 | Jardiance |
| Pfizer INC. | $840.68 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $722.07 | 2019-2024 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $695.06 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $582.54 | 2019-2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $507.96 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $425.18 | 2019-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $377.57 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $315.14 | 2021-2024 | Verquvo, Winrevair |
| Boston Scientific Corporation | $312.20 | 2020-2025 | Emblem Mri S-Icd, Watchman Flx, Watchman Access System |
| Amarin Pharma, INC. | $286.37 | 2019-2021 | |
| Edwards Lifesciences Corporation | $209.20 | 2019-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien Xt Transcatheter Heart Valve (Thv) |
| Biotronik INC. | $160.93 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $132.22 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $130.70 | 2019 | |
| Vifor Pharma, INC. | $125.48 | 2019-2021 | |
| Scpharmaceuticals INC. | $121.42 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $106.73 | 2019-2024 | Farxiga |
| Impulse Dynamics (USA) INC. | $100.42 | 2023-2024 | Optimizer, Optimizer |
| Novo Nordisk INC | $99.54 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Alnylam Pharmaceuticals INC. | $51.77 | 2022-2023 | Onpattro |
| Lexicon Pharmaceuticals, INC. | $47.19 | 2023-2024 | Inpefa |
| Abiomed | $26.20 | 2024 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $26.00 | 2022 | |
| Daiichi Sankyo INC. | $25.13 | 2023 | Injectafer |
| Abbott Laboratories | $21.41 | 2021 | |
| Akcea Therapeutics, INC. | $18.34 | 2020 | |
| Medtronic, INC. | $18.24 | 2021 | |
| Kestra Medical Technology Services, INC. | $18.23 | 2022 | |
| Astellas Pharma US INC | $17.50 | 2021 | |
| Amryt Pharma Holdings LTD | $16.56 | 2021 | |
| Inogen, INC. | $14.45 | 2022 | |
| Medtronic Vascular, INC. | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gianfagna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.